These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 15122732)

  • 21. Data handling in clinical trials: an ongoing debate.
    Jongen PJ
    Mult Scler; 1995; 1 Suppl 1():S60-3. PubMed ID: 9345402
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Data Monitoring Committees: Current issues.
    Fleming TR; Ellenberg SS; DeMets DL
    Clin Trials; 2018 Aug; 15(4):321-328. PubMed ID: 29629815
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Data and safety monitoring boards: academic credit where credit is due?
    Armstrong PW; Califf RM
    JAMA; 2013 Oct; 310(15):1563-4. PubMed ID: 24129461
    [No Abstract]   [Full Text] [Related]  

  • 24. Management and interpretation of data obtained from clinical trials in pain management.
    Theodore BR; Gatchel RJ
    Pain Pract; 2008; 8(6):461-72. PubMed ID: 19000174
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The scribe of stroke trials.
    van Gijn J
    Eur Neurol; 2003; 49(2):125-7. PubMed ID: 12584424
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [DSMB. 1. What role, what responsibilities?].
    Brun-Buisson C
    Med Sci (Paris); 2005 Jan; 21(1):78-82. PubMed ID: 15639025
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An introductory note to CHMP guidelines: choice of the non-inferiority margin and data monitoring committees.
    Brown D; Volkers P; Day S
    Stat Med; 2006 May; 25(10):1623-7. PubMed ID: 16639776
    [TBL] [Abstract][Full Text] [Related]  

  • 28. When should data and safety monitoring committees share interim results in cardiovascular trials?
    Borer JS; Gordon DJ; Geller NL
    JAMA; 2008 Apr; 299(14):1710-2. PubMed ID: 18398083
    [No Abstract]   [Full Text] [Related]  

  • 29. [Monitoring the safety of participants in randomised clinical trials: basis and methods].
    Tijssen JG
    Ned Tijdschr Geneeskd; 2008 Mar; 152(12):674-8. PubMed ID: 18438062
    [TBL] [Abstract][Full Text] [Related]  

  • 30. When should an interim analysis be unblinded to the data monitoring committee?
    Knottnerus JA; Spigt MG
    J Clin Epidemiol; 2010 Apr; 63(4):350-2. PubMed ID: 19762210
    [No Abstract]   [Full Text] [Related]  

  • 31. Information-based monitoring of clinical trials.
    Tsiatis AA
    Stat Med; 2006 Oct; 25(19):3236-44; discussion 3320-5, 3326-47. PubMed ID: 16927248
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The independent statistician model: How well is it working?
    DeMets D
    Clin Trials; 2018 Aug; 15(4):329-334. PubMed ID: 29741390
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A decision rule for sequential monitoring of clinical trials with a primary and supportive outcome.
    Zhao Y; Grambsch PM; Neaton JD
    Clin Trials; 2007; 4(2):140-53. PubMed ID: 17456513
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regulatory perspectives on data safety monitoring boards: protecting the integrity of data.
    Hemmings R; Day S
    Drug Saf; 2004; 27(1):1-6. PubMed ID: 14720083
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The other side of clinical trial monitoring; assuring data quality and procedural adherence.
    Williams GW
    Clin Trials; 2006; 3(6):530-7. PubMed ID: 17170037
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Committee for Medicinal Products for Human Use (CHMP) guideline on Data Monitoring Committees.
    ; ;
    Stat Med; 2006 May; 25(10):1639-45. PubMed ID: 16639775
    [No Abstract]   [Full Text] [Related]  

  • 37. Cell-based interventions for neurologic conditions: ethical challenges for early human trials.
    Mathews DJ; Sugarman J; Bok H; Blass DM; Coyle JT; Duggan P; Finkel J; Greely HT; Hillis A; Hoke A; Johnson R; Johnston M; Kahn J; Kerr D; Kurtzberg J; Liao SM; McDonald JW; McKhann G; Nelson KB; Rao M; Regenberg A; Siegel AW; Smith K; Solter D; Song H; Vescovi A; Young W; Gearhart JD; Faden R
    Neurology; 2008 Jul; 71(4):288-93. PubMed ID: 18463365
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Data monitoring committees for pragmatic clinical trials.
    Ellenberg SS; Culbertson R; Gillen DL; Goodman S; Schrandt S; Zirkle M
    Clin Trials; 2015 Oct; 12(5):530-6. PubMed ID: 26374679
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical trial registration.
    Harms M
    Physiotherapy; 2011 Sep; 97(3):181. PubMed ID: 21820534
    [No Abstract]   [Full Text] [Related]  

  • 40. An introductory note to the CHMP guidelines: choice of the non-inferiority margin and data monitoring committees by David Brown, Peter Volkers and Simon Day, Statistics in Medicine 2006; 25:1623-1627.
    Stat Med; 2007 Jan; 26(1):230-3; author reply 234-5. PubMed ID: 16900566
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.